Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rian Dickstein

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Urologic Oncology|November 24, 2022
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomesSolomon L Woldu, Craig Labbate, Katie S Murray, et al.
Urologic Oncology|January 21, 2025
Durability of response of UGN-101: Longitudinal follow up of multicenter studySolomon L Woldu, Daniel Igel, Brett Johnson, et al.
Nature Medicine|June 6, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
Nature Medicine|June 18, 2024
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
Nature Medicine|July 2, 2024
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
Urologic Oncology|December 13, 2023
Interruptions in bladder cancer care during the COVID-19 public health emergencyJohn L Gore, Kristin Follmer, Jason Reynolds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2025
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder CancerJohn L Gore, Erika M Wolff, Michael G Nash, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Urologic Oncology|November 24, 2022
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomesSolomon L Woldu, Craig Labbate, Katie S Murray, et al.
Urologic Oncology|January 21, 2025
Durability of response of UGN-101: Longitudinal follow up of multicenter studySolomon L Woldu, Daniel Igel, Brett Johnson, et al.
Nature Medicine|June 6, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
Nature Medicine|June 18, 2024
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
Nature Medicine|July 2, 2024
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
Urologic Oncology|December 13, 2023
Interruptions in bladder cancer care during the COVID-19 public health emergencyJohn L Gore, Kristin Follmer, Jason Reynolds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2025
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder CancerJohn L Gore, Erika M Wolff, Michael G Nash, et al.
Pageof 2